Tristan Maurina

Randomized, Placebo-Controlled, Phase III Trial of Sunitinib Plus Prednisone Versus Prednisone Alone in Progressive, Metastatic, Castration-Resistant Prostate Cancer

M. Dror Michaelson, Stéphane Oudard, Yen-Chuan Ou et al. · Journal of Clinical Oncology · 2013 · 190 citations

Medicine, Oncology, Pharmacology +14

Clinical impact of targeted therapies in patients with metastatic clear-cell renal cell carcinoma

Virginie Nerich, Marion Hugues, Thierry Nai et al. · OncoTargets and Therapy · 2014 · 78 citations · Full text

Medicine, Oncology, Genitourinary Oncology +15

Randomized, placebo-controlled, phase III trial of sunitinib in combination with prednisone (SU+P) versus prednisone (P) alone in men with progressive metastatic castration-resistant prostate cancer (mCRPC).

Yang Ou, M. Dror Michaelson, L. Sengeløv et al. · Journal of Clinical Oncology · 2011 · 56 citations

Medicine, Oncology, Pharmacology +17

Rapalogs Efficacy Relies on the Modulation of Antitumor T-cell Immunity

Laurent Beziaud, Laura Mansi, Patrice Ravel et al. · Cancer Research · 2016 · 49 citations

Medicine, Oncology, Pharmacology +17

Phase I Safety and Pharmacodynamic of Inecalcitol, a Novel VDR Agonist with Docetaxel in Metastatic Castration-Resistant Prostate Cancer Patients

Jacques Médioni, G. Deplanque, Jean-­Marc Ferrero et al. · Clinical Cancer Research · 2014 · 43 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17